Last reviewed · How we verify
NCT04961528: ACTIVE
ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
Phase 3 trial testing Tranexamic Acid 500 MG in Hemoptysis in 315 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 315 |
| Start date | 27 March 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- Tranexamic Acid 500 MG — full drug profile →
- Terlipressin — full drug profile →
- Placebo
Conditions studied
- Hemoptysis — all drugs for Hemoptysis →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
Adults 18 to 90, any sex, with Hemoptysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims is to verify the hypothetize that inhaled Tranexamic Acid (TXA) or Terlipressin (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. This randomized double-blind multicenter triple arm trial compares the administration of TXA to TER to placebo in patients with mild to severe hemoptysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04961528
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tranexamic Acid 500 MG
Trials testing the same drug.
- NCT06246422 — Tranexamic Acid Instillation in Laparoscopic Cholecystectomy · NA · completed
- NCT04521881 — Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults · Phase 3 · recruiting
- NCT04742205 — ITCH Trial: Protocol for a Randomized, Double Blind Placebo-controlled Trial · Phase 2, PHASE3 · completed
- NCT05897918 — Tranexamic Acid in Treatment of Facial Erythema · NA · completed
- NCT03690037 — Investigating the Effect of Intravenous and Oral Tranexamic Acid on Blood Loss After Primary Hip and Knee Arthroplasty · Phase 4 · completed
Other recruiting trials for Hemoptysis
Currently open trials in the same condition.
- NCT05634200 — Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan (ULYSSES) · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04961528 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 3 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04961528.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing